权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity

制定策略来抑制癌症免疫治疗引起的免疫相关不良事件而不妨碍抗肿瘤免疫

基本信息

批准号：
10553680
负责人：
Arabella Young
金额：
$ 24.9万
依托单位：
UNIVERSITY OF UTAH
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10553680
关键词：
Age Autoimmune Autoimmune Diseases Autoimmunity California Cancer Patient Circadian Rhythms Clinical Combined Modality Therapy Complex Data Set Development Diet Disease Engineering Environment Environmental Impact Environmental Risk Factor Epigenetic Process Etiology Event Exposure to Follow-Up Studies Fostering Frequencies Genetic Genetic Predisposition to Disease Goals Health Care Costs Homeostasis Immune Immune Evasion Immune response Immune system Immunity Immunoprecipitation Immunotherapy Inbred NOD Mice Insulin-Dependent Diabetes Mellitus Malignant Neoplasms Mediating Mentorship Modality Modeling Molecular Morbidity - disease rate Mouse Strains Mus Neoplasm Transplantation Non obese Pathology Pathway interactions Patients Phase Positioning Attribute Pre-Clinical Model Regimen Reporting Research Resistance Risk Role Safety San Francisco Scientist Self Tolerance Severities Specificity Stress Susceptibility Gene T cell receptor repertoire sequencing Therapeutic Tissues Training Transplantation Treatment Efficacy Tumor Cell Line Tumor Immunity Universities anti-CTLA4 anti-tumor immune response body system cancer care cancer immunotherapy cancer therapy cancer type combinatorial design diabetic dimensional analysis genetic profiling high dimensionality immune activation immune cell infiltrate immune checkpoint immune function immune-related adverse events immunomodulatory therapies immunotoxicity improved insight microbiome mortality mouse model multidimensional data novel therapeutics pre-clinical preclinical development preservation prevent programmed cell death protein 1 programs resistance mechanism response safety assessment side effect single-cell RNA sequencing skills success survival outcome treatment strategy tumor tumor microenvironment tumor-immune system interactions

项目摘要

Project Summary/Abstract Tumors elicit a range of suppressive mechanisms in order to evade the immune system. Many of these are targetable as evidenced by the great success of cancer immunotherapies that boost a patient's own immune response towards cancer. Often, targets for cancer immunotherapies represent pathways that at homeostasis protect against activation of an immune response towards self, limiting the development of autoimmune disease. Cancer patients treated with immune-potentiating therapies are exposed to significant risk of developing immune-related adverse events (irAEs). These irAEs have been reported in nearly every organ system, and in many cases represent non-resolving autoimmune side-effects that pose a significant impact due to their potential morbidity, mortality and associated healthcare costs. With a growing number of immunotherapies reaching clinical utility and increasing combination studies that may initiate more frequent and severe irAEs, understanding which therapeutic approaches provide improved tumor control with minimal side-effects is essential. In this study, by generating transplantable, syngeneic tumor cell lines in autoimmune- prone NOD mice, which develop autoimmune pathologies in response to cancer immunotherapies, we may begin to assess the interplay between irAEs and anti-tumor immunity. In-depth profiling of genetic, epigenetic and cellular mechanisms that separate anti-tumor immunity versus autoimmunity in response to cancer immunotherapies will be defined to better engineer therapeutic strategies that enhance the immune response towards tumor with limited impact towards self. Using NOD tumors resistant to clinically-approved cancer immunotherapies such as anti-PD-1 and anti-CTLA-4, combination therapeutic strategies that reinvigorate immune activation in the tumor microenvironment will be identified and the associated risk for precipitating irAEs determined. Together, these preclinical models provide a platform to assess safety profiles for cancer immunotherapies, identifying mechanisms to inhibit or avoid irAEs while preserving anti-tumor immunity. This research will be performed amongst world-class scientists and facilities at the University of California, San Francisco, this environment will foster expert training in the analysis of high-dimensional datasets generated from CyTOF and 10X single-cell RNA and TCR sequencing, an essential skill for delineating the complex mechanisms contributing to immune-mediated disease. Both my mentorship committee, led by Dr. Jeffrey Bluestone and expert collaborators will allow me to fulfil these research goals. Following, I will transition to an independent position establishing a research program that integrates the effect of multiple environmental factors, including microbiome, diet, age and stress, alongside autoimmune and anti-tumor immune responses to cancer immunotherapy using the NOD tumor models that have been developed, with the ultimate aim to improve safety, specificity and treatment efficacy for immunotherapy-treated cancer patients.

项目总结/文摘